WeVote
Log In

Bill

Bill

SF 205

Antineoplastic cancer treatment prior authorization prohibition

2025-2026 Regular Session Introduced by Liz Boldon and 3 co-sponsors

Prohibits insurers from requiring prior authorization before covering cancer drug treatments, enabling faster patient access but removing cost-control review mechanisms.

Comm report: To pass as amended and re-refer to Health and Human Services
#commerceandcommercedepartment #hospitalsandhealthcarefacilities #insurance-health
0
WeVote Research Nonpartisan
Bill Summary · SF 205

Legislative bill overview

SF 205 prohibits health insurance companies from requiring prior authorization for antineoplastic (cancer-fighting) drugs and treatments. The bill streamlines access to cancer medications by removing the approval barrier that insurers currently use before covering these drugs, allowing patients and oncologists to proceed with treatment without delay.

Why is this important

Cancer treatment is time-sensitive, and prior authorization delays can mean weeks without therapy while insurers review medical necessity. This bill directly affects thousands of Minnesota cancer patients by potentially reducing treatment delays and reducing administrative burden on oncology practices, though it also removes insurers' ability to question potentially unnecessary or experimental treatments upfront.

Potential points of contention

  • Cost implications: Eliminating prior authorization removes a cost-control mechanism; insurers argue this could increase premiums or out-of-pocket costs if more expensive cancer drugs are used without pre-approval review
  • Scope questions: The bill may not clarify which specific drugs qualify as "antineoplastic" or how newer immunotherapy treatments are categorized, creating implementation ambiguity
  • Insurance company pushback: Insurers will likely argue prior authorization protects against inappropriate prescribing and that some review processes can be expedited rather than eliminated entirely

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.